BEAM logo

Beam Therapeutics Inc. Common Stock


BEAM: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.


Show BEAM Financials

Consumer Interest
SEC Filings

Recent trades of BEAM by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by BEAM's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compositions and methods for treating hemoglobinopathies May. 31, 2022
  • Patent Title: Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence Oct. 26, 2021
  • Patent Title: Compositions and methods for treating hemoglobinopathies Oct. 12, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of BEAM in WallStreetBets Daily Discussion


Recent insights relating to BEAM

CNBC Recommendations

Recent picks made for BEAM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BEAM

Corporate Flights

Flights by private jets registered to BEAM